Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive collaboration agreement. Under the agreement, Belief BioMed will grant Grand Life ...
Although malaria elimination has been reported in 14 countries, human health risk reduction against vector-borne diseases remains dire. With neither effective treatment nor widely available ...
Applied Biopharm Consulting Ltd has been awarded an Intellectual Property (IP) Start Grant from the Local Enterprise Office under Enterprise Ireland’s IP Strategy initiative. The grant will support ...
Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research ...
SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector ...
Belief BioMed (BBM) today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially ...
Detailed price information for Oxford Biomedica Plc New (OXBDF) from The Globe and Mail including charting and trades.
The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.
When a virus infects a bacterial cell, the viral genome is the first component to be fully injected into the cell, making it an ideal immune target. A bacterial enzyme anchored to the membrane ...
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results